| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Lujain Bader Eddin, M F Nagoor Meeran, Sandeep B Subramanya, Niraj Kumar Jha, Shreesh Ojh. Therapeutic potential of agents targeting cannabinoid type 2 receptors in organ fibrosis. Pharmacology research & perspectives. vol 12. issue 6. 2024-10-19. PMID:39425446. |
cannabinoid receptors type 2 (cb2) are a class of g protein-coupled receptors responsible for transmitting intracellular signals triggered by both endogenous and exogenous cannabinoids, including those derived from plants (phytocannabinoids) or manufactured synthetically (synthetic cannabinoids). |
2024-10-19 |
2024-10-21 |
Not clear |
| Rachel Luba, Gabriela Madera, Rebecca Schusterman, Andrew Kolodziej, Ian Hodgson, Sandra D Come. Evaluating the Abuse Potential of Lenabasum, a Selective Cannabinoid Receptor 2 Agonist. The Journal of pharmacology and experimental therapeutics. vol 391. issue 2. 2024-10-18. PMID:38936978. |
endocannabinoids, which are present throughout the central nervous system (cns), can activate cannabinoid receptors 1 and 2 (cb1 and cb2). |
2024-10-18 |
2024-10-21 |
human |
| Mayur B Kale, Mohit D Umare, Nitu L Wankhede, Rohitas Deshmukh, Vikrant Abbot, Md Khalid Anwer, Brijesh G Taksande, Aman B Upaganlawar, Milind J Umekar, Seema Ramniwas, Monica Gulati, Rashmi Arora, Tapan Beh. Decoding the Therapeutic Potential of Cannabis and Cannabinoids in Neurological Disorders. Current pharmaceutical design. 2024-10-16. PMID:39410886. |
this neuroprotective effect is orchestrated through numerous g protein-coupled receptors (gpcrs) and the two cannabinoid receptors, cb1 and cb2. |
2024-10-16 |
2024-10-18 |
Not clear |
| Mayur B Kale, Mohit D Umare, Nitu L Wankhede, Rohitas Deshmukh, Vikrant Abbot, Md Khalid Anwer, Brijesh G Taksande, Aman B Upaganlawar, Milind J Umekar, Seema Ramniwas, Monica Gulati, Rashmi Arora, Tapan Beh. Decoding the Therapeutic Potential of Cannabis and Cannabinoids in Neurological Disorders. Current pharmaceutical design. 2024-10-16. PMID:39410886. |
the intricate interplay of cannabinoids with the endocannabinoid system, involving cb1 and cb2 receptors, underscores the need for precise understanding and targeted approaches. |
2024-10-16 |
2024-10-18 |
Not clear |
| Yuqing Wang, Ming Cao, Yuanyuan Zhang, Qian Chen, Zhaojie Chen, Ji Ji. The CB2-PKC pathway is involved in esketamine-induced anti-inflammation in BV-2 microglial cells exposed to lipopolysaccharides. American journal of translational research. vol 16. issue 9. 2024-10-14. PMID:39398580. |
the aim of this study was to explore whether microglial cannabinoid type 2 (cb2) receptor and protein kinase c (pkc) are involved in the antidepressant effects of esk. |
2024-10-14 |
2024-10-16 |
Not clear |
| Prince Ofori, Natalia Zemliana, Ilan Zaffran, Tatiana Etzion, Ronit Vogt Sionov, Doron Steinberg, Raphael Mechoulam, Natalya M Kogan, Francesca Levi-Schaffe. Antifungal properties of Abnormal Cannabinoid derivatives: Disruption of Biofilm Formation and Gene Expression in Candida Species. Pharmacological research. 2024-10-05. PMID:39368567. |
abnormal cannabinoids (including comp 3) are a class of synthetic lipid compounds with non-psychoactive properties and regioisomer configurations, but distinct from traditional cannabinoids since they do not interact with the established cb1 and cb2 receptors. |
2024-10-05 |
2024-10-08 |
mouse |
| Constanza Suárez-Suárez, Sebastián González-Pérez, Valeria Márquez-Miranda, Ingrid Araya-Duran, Isabel Vidal-Beltrán, Sebastián Vergara, Ingrid Carvacho, Fernando Hinostroz. The Endocannabinoid Peptide RVD-Hemopressin Is a TRPV1 Channel Blocker. Biomolecules. vol 14. issue 9. 2024-09-28. PMID:39334900. |
rvd-hemopressin (rvd-hp), a novel peptide identified in noradrenergic neurons, modulates cannabinoid receptors cb1 and cb2. |
2024-09-28 |
2024-10-01 |
Not clear |
| Valerie Joers, Benjamin C Murray, Caroline McLaughlin, Danielle Oliver, Hannah E Staley, Jazmyn Coronado, Cindy Achat-Mendes, Sanam Golshani, Sean D Kelly, Matthew Goodson, Danica Lee, Fredric P Manfredsson, Bob M Moore Ii, Malú Gámez Tanse. Modulation of cannabinoid receptor 2 alters neuroinflammation and reduces formation of alpha-synuclein aggregates in a rat model of nigral synucleinopathy. Journal of neuroinflammation. vol 21. issue 1. 2024-09-28. PMID:39334169. |
cannabinoid receptor-2 (cb2) is highly expressed on activated microglia and peripheral immune cells, is upregulated in the substantia nigra of individuals with pd and in mouse models of nigral degeneration. |
2024-09-28 |
2024-10-01 |
mouse |
| Rayees Ahmad Naikoo, Ritu Painuli, Zaheen Akhter, Parvinder Pal Sing. Cannabinoid receptor 2 (CB2) modulators: A patent review (2016-2024). Bioorganic chemistry. vol 153. 2024-09-17. PMID:39288632. |
cannabinoid receptors cb1 and cb2 play critical roles in regulating numerous central and peripheral physiological activities. |
2024-09-17 |
2024-09-20 |
Not clear |
| Rayees Ahmad Naikoo, Ritu Painuli, Zaheen Akhter, Parvinder Pal Sing. Cannabinoid receptor 2 (CB2) modulators: A patent review (2016-2024). Bioorganic chemistry. vol 153. 2024-09-17. PMID:39288632. |
despite several cb2 receptor ligands entering clinical trials, none have achieved market approval except natural cannabinoids and their derivatives, primarily due to insufficient cb2/cb1 receptor selectivity. |
2024-09-17 |
2024-09-20 |
Not clear |
| Kanchan Bala, Pratyush Porel, Khadga Raj Ara. Emerging roles of cannabinoid receptor CB2 receptor in the central nervous system: therapeutic target for CNS disorders. Psychopharmacology. 2024-09-12. PMID:39264450. |
cannabinoid 2 receptors (cb2) are expressed in the central nervous system (cns) on microglia and subgroups of neurons and are involved in various behavioural processes via immunological and neural regulation. |
2024-09-12 |
2024-09-14 |
Not clear |
| Haruka Hosoki, Toru Asahi, Chihiro Nozak. Cannabinoid CB2 receptors enhance high-fat diet evoked peripheral neuroinflammation. Life sciences. 2024-08-22. PMID:39173999. |
cannabinoid cb2 receptors enhance high-fat diet evoked peripheral neuroinflammation. |
2024-08-22 |
2024-08-25 |
mouse |
| Haruka Hosoki, Toru Asahi, Chihiro Nozak. Cannabinoid CB2 receptors enhance high-fat diet evoked peripheral neuroinflammation. Life sciences. 2024-08-22. PMID:39173999. |
it is known that the cannabinoid type 2 (cb2) receptor has an anti-inflammatory role. |
2024-08-22 |
2024-08-25 |
mouse |
| Andrea Chicca, Daniel Bátora, Christoph Ullmer, Antonello Caruso, Sabine Grüner, Jürgen Fingerle, Thomas Hartung, Roland Degen, Matthias Müller, Uwe Grether, Pal Pacher, Jürg Gertsc. A Highly Potent, Orally Bioavailable Pyrazole-Derived Cannabinoid CB2 Receptor- Selective Full Agonist for ACS pharmacology & translational science. vol 7. issue 8. 2024-08-15. PMID:39144568. |
a highly potent, orally bioavailable pyrazole-derived cannabinoid cb2 receptor- selective full agonist for the cannabinoid cb2 receptor (cb2r) is a potential therapeutic target for distinct forms of tissue injury and inflammatory diseases. |
2024-08-15 |
2024-08-17 |
Not clear |
| Fabienne Briand-Mésange, Isabelle Gennero, Juliette Salles, Stéphanie Trudel, Lionel Dahan, Jérôme Ausseil, Bernard Payrastre, Jean-Pierre Salles, Hugues Cha. From Classical to Alternative Pathways of 2-Arachidonoylglycerol Synthesis: AlterAGs at the Crossroad of Endocannabinoid and Lysophospholipid Signaling. Molecules (Basel, Switzerland). vol 29. issue 15. 2024-08-10. PMID:39125098. |
2-arachidonoylglycerol (2-ag) is the most abundant endocannabinoid (ec), acting as a full agonist at both cb1 and cb2 cannabinoid receptors. |
2024-08-10 |
2024-08-13 |
Not clear |
| Basak Isildar, Alisa Bahar Beydogan, Ece Koyuturk, Zeynep Mine Coskun Yazici, Meral Koyuturk, Sema Bolken. Effects of ∆-9 tetrahydrocannabinol on the small intestine altered by high fructose diet: A Histopathological study. Histochemistry and cell biology. 2024-08-07. PMID:39110194. |
∆9-tetrahydrocannabinol (thc), a key cannabinoid, interacts with cb1 and cb2 receptors in the gastrointestinal tract, potentially mitigating inflammation. |
2024-08-07 |
2024-08-09 |
rat |
| Bruna R Kouba, Glorister A Altê, Ana Lúcia S Rodrigue. Putative Pharmacological Depression and Anxiety-Related Targets of Calcitriol Explored by Network Pharmacology and Molecular Docking. Pharmaceuticals (Basel, Switzerland). vol 17. issue 7. 2024-07-27. PMID:39065743. |
the main targets found are the vitamin d receptor (vdr), histamine h3 receptor (h3r), endocannabinoid receptors 1 and 2 (cb1 and cb2), nuclear receptor nr1h3, patched-1 (ptch1) protein, opioid receptor nop, and phosphodiesterase enzymes pde3a and pde5a. |
2024-07-27 |
2024-07-29 |
Not clear |
| Willias Masocha, Esraa Aly, Aisha Albaloushi, Altaf Al-Romaiya. Licofelone, a Dual COX/LOX Inhibitor, Ameliorates Paclitaxel-Induced Mechanical Allodynia in Rats in a Cannabinoid Receptor-Dependent Manner. Biomedicines. vol 12. issue 7. 2024-07-27. PMID:39062118. |
molecular docking showed that licofelone binds to both cb1 and cb2 receptors with a high affinity similar to the phytocannabinoid 1-trans-delta-9-tetrahydrocannabinol and the synthetic cannabinoid win 55,212-2. |
2024-07-27 |
2024-07-29 |
mouse |
| Man Liu, Dong Pan, MengYa Wang, Han Deng, ZeGang M. JWH133 attenuates behavior deficits and iron accumulation in the 6-OHDA-induced Parkinson's disease model rats. Journal of neurophysiology. 2024-07-17. PMID:39015077. |
growing evidence indicated that activation of cannabinoid type 2 (cb2) receptors protect dopamine neurons in the pathogenesis of parkinson's disease (pd). |
2024-07-17 |
2024-07-19 |
rat |
| Hikari Tachibana, Moeka Nomura, Takeshi Funakoshi, Kana Unuma, Toshihiko Aki, Koichi Uemur. Incomplete autophagy and increased cholesterol synthesis during neuronal cell death caused by a synthetic cannabinoid, CP-55,940. Neurotoxicology. 2024-06-28. PMID:38942151. |
cp-55,940, a synthetic cannabinoid having the ability to activate both cb1 and cb2 receptors, has been shown to induce cell death in neurons as well as other cells. |
2024-06-28 |
2024-07-01 |
mouse |